UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

European journal of cancer (1990), 2014-11, Vol.50, p.128-128

2014

Volltextzugriff (PDF)

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

Annals of oncology, 2018-10, Vol.29, p.viii70-viii70

2018

Volltextzugriff (PDF)

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S548-S548

2015

Volltextzugriff (PDF)

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

European journal of cancer (1990), 2012-11, Vol.48, p.114-115

2012

Volltextzugriff (PDF)

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

European journal of cancer (1990), 2012-11, Vol.48, p.115-115

2012

Volltextzugriff (PDF)

PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?

European journal of cancer (1990), 2011, Vol.47, p.S16-S16

2011

Volltextzugriff (PDF)

P068 Sequencing to identify potential targets of resistance to primary therapy

Breast (Edinburgh), 2015-03, Vol.24, p.S50-S50

2015

Volltextzugriff (PDF)

P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy

Breast (Edinburgh), 2015-03, Vol.24, p.S43-S43

2015

Volltextzugriff (PDF)

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

European journal of cancer (1990), 2011, Vol.47, p.S17-S17

2011

Volltextzugriff (PDF)

S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank

European journal of cancer supplements, 2007, Vol.5 (8), p.5-5

Leyland-Jones, B

2007

Volltextzugriff (PDF)

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

Breast (Edinburgh), 2009, Vol.18, p.S11-S11

2009

Volltextzugriff (PDF)

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

European journal of cancer supplements, 2008, Vol.6 (12), p.72-72

2008

Volltextzugriff (PDF)

Abstract P2-03-11: Genetic background determines the algorithm of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-03-11

2019

Volltextzugriff (PDF)

Abstract P2-03-08: Preclinical evaluation of the PI3Kα/δ inhibitor, copanlisib in HER2+ breast cancer: A proof of concept study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-03-08

2019

Volltextzugriff (PDF)

Abstract P2-03-06: PTEN expression at the nexus of oncogenic signals in TNBC: Testing combination of p110beta-isoform-specific inhibitor with five PARP inhibitors

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-03-06

2019

Volltextzugriff (PDF)

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours

British journal of cancer, 2014-08

2014

Volltextzugriff (PDF)

Abstract P5-20-18: Comparison of paclitaxel plus T-DM1 and pertuzumab versus paclitaxel plus trastuzumab and pertuzumab with carboplatin for HER2 overexpressed breast cancer models

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-20-18

2018

Volltextzugriff (PDF)

Abstract PD8-10: APOBEC mutation signature in breast cancer correlates with tumor mutation burden and poor responses to therapy

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD8-10-PD8-10

2018

Volltextzugriff (PDF)

Abstract P1-03-04: Role of PTEN and BRCA1 as determinants of synergy for the combination of vistusertib with carboplatin and olaparib in TNBC

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-03-04

2018

Volltextzugriff (PDF)

Deletions at 1P13.3 is Associated with Significantly Adverse Prognosis in Breast Cancer

Annals of oncology, 2013-05, Vol.24, p.iii29

2013

Volltextzugriff (PDF)

Abstract P6-08-07: Gain and amplification of RAC1 GTP-ase in BC: Explaining alterations in patients by experiments using TNBC model

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-08-07

2017

Volltextzugriff (PDF)

Abstract P6-08-09: Cancer stem cells define 3D clonogenic growth response to rational combinations of PI3K-isoform specific inhibitors in TNBC

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-08-09

2017

Volltextzugriff (PDF)

Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer

Gynecologic oncology, 2019-06, Vol.154, p.31-32

2019

Volltextzugriff (PDF)

42PLOW EXPRESSION OF FGD3, A PUTATIVE GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR CDC42, IS PROGNOSTIC OF POOR OUTCOME IN BREAST CANCER

Annals of oncology, 2014-05, Vol.25 (suppl_1), p.i14-i14

2014

Volltextzugriff (PDF)

Low Expression of FGD3, a Putative Guanine Nucleotide Exchange Factor for CDC42, is Prognostic of Poor Outcome in Breast Cancer

Annals of oncology, 2014-05, Vol.25, p.i18-i18

2014

Volltextzugriff (PDF)

1 – 25 von 168

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(20)
Biological And Medical Sciences
(13)
Hematology, Oncology And Palliative Medicine
(13)
Medical Sciences
(13)
Pharmacology. Drug Treatments
(12)
Female
(9)
Chemotherapy
(8)
Animals
(7)
Antineoplastic Agents
(7)
Drug Evaluation
(6)
Male
(6)
Mice
(4)
Neoplasms - Drug Therapy
(4)
Adult
(3)
Antineoplastic Agents - Pharmacology
(3)
Breast Cancer
(3)
Clinical Trials As Topic
(3)
Gene Expression Regulation, Neoplastic
(3)
Middle Aged
(3)
Adolescent
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?

P068 Sequencing to identify potential targets of resistance to primary therapy

P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

Abstract P2-03-11: Genetic background determines the algorithm of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor

Abstract P2-03-08: Preclinical evaluation of the PI3Kα/δ inhibitor, copanlisib in HER2+ breast cancer: A proof of concept study

Abstract P2-03-06: PTEN expression at the nexus of oncogenic signals in TNBC: Testing combination of p110beta-isoform-specific inhibitor with five PARP inhibitors

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours

Abstract P5-20-18: Comparison of paclitaxel plus T-DM1 and pertuzumab versus paclitaxel plus trastuzumab and pertuzumab with carboplatin for HER2 overexpressed breast cancer models

Abstract PD8-10: APOBEC mutation signature in breast cancer correlates with tumor mutation burden and poor responses to therapy

Abstract P1-03-04: Role of PTEN and BRCA1 as determinants of synergy for the combination of vistusertib with carboplatin and olaparib in TNBC

Deletions at 1P13.3 is Associated with Significantly Adverse Prognosis in Breast Cancer

Abstract P6-08-07: Gain and amplification of RAC1 GTP-ase in BC: Explaining alterations in patients by experiments using TNBC model

Abstract P6-08-09: Cancer stem cells define 3D clonogenic growth response to rational combinations of PI3K-isoform specific inhibitors in TNBC

Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer

42PLOW EXPRESSION OF FGD3, A PUTATIVE GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR CDC42, IS PROGNOSTIC OF POOR OUTCOME IN BREAST CANCER

Low Expression of FGD3, a Putative Guanine Nucleotide Exchange Factor for CDC42, is Prognostic of Poor Outcome in Breast Cancer

Aktive Filter

Suchergebnisse filtern